Cariprazine delay

The FDA set up a potentially serious roadblock for Forest Laboratories and its partner Gedeon Richter, rejecting their application for the schizophrenia/bipolar drug cariprazine and likely delaying any possible approval until the agency gets additional clinical trial data.

A New Drug Application for cariprazine has been accepted by the US FDA. A decision is expected in the first half of 2015

NDA article1

I hope that this drug will not prove itself to be just another useless activating atypical that I probably wont be able to take - the newer meds are so stimulating! I dont see how this is going to help my anxiety and insomnia or mania in any way

1 Like

It does have possible side effects of restlessness and insomnia for some who were in the trial.
Still, it might help some people.